(FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q3)Mar 31, 2021 | (FY)Dec 31, 2020 | (Q3)Mar 31, 2020 | (FY)Dec 31, 2019 | (FY)Dec 31, 2018 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -1.07%621.02M | -3.19%314.01M | 7.71%627.73M | --324.36M | 44.67%582.8M | 45.02%104.18M | 25.44%402.84M | --71.84M | 13.87%321.15M | --282.03M |
Operating income | -1.07%621.02M | -3.19%314.01M | 7.71%627.73M | 324.36M | 44.67%582.8M | 45.02%104.18M | 25.44%402.84M | 71.84M | 13.87%321.15M | 282.03M |
Cost of sales | ---- | ---- | ---- | ---- | -34.57%-434.95M | -47.16%-80.67M | -21.91%-323.22M | ---54.82M | -12.46%-265.12M | ---235.76M |
Operating expenses | -5.36%-503.96M | 0.36%-246.09M | -9.97%-478.32M | -246.98M | -34.57%-434.95M | -47.16%-80.67M | -21.91%-323.22M | -54.82M | -12.46%-265.12M | -235.76M |
Gross profit | -21.65%117.07M | -12.23%67.93M | 1.06%149.41M | 77.39M | 85.69%147.85M | 38.13%23.52M | 42.12%79.62M | 17.02M | 21.06%56.02M | 46.28M |
Administrative expenses | -10.16%-55.3M | -4.66%-20.1M | 4.79%-50.2M | ---19.21M | -93.43%-52.72M | -114.59%-7.35M | -23.93%-27.26M | ---3.43M | -38.40%-21.99M | ---15.89M |
Research and development expenses | 17.52%-4.23M | 6.68%-2.21M | ---5.12M | ---2.36M | ---- | ---- | ---- | ---- | ---- | ---- |
Impairment and provision | -61.72%-8.54M | -43.57%-6.38M | -40.62%-5.28M | ---4.45M | -1,732.68%-3.76M | -9.54%-1.05M | 6.82%-205K | ---954K | 68.57%-220K | ---700K |
-Other impairment is provision | -61.72%-8.54M | -43.57%-6.38M | -40.62%-5.28M | ---4.45M | -1,732.68%-3.76M | -9.54%-1.05M | 6.82%-205K | ---954K | 68.57%-220K | ---700K |
Special items of operating profit | -25.51%2.81M | -32.45%911.21K | 14.31%3.77M | --1.35M | 79.52%3.3M | 234.68%415K | 83.97%1.84M | --124K | 390.96%998K | ---343K |
Operating profit | -46.77%46.77M | -26.95%37.15M | -7.19%87.86M | 50.85M | 75.32%94.66M | 21.66%15.53M | 55.12%53.99M | 12.77M | 18.63%34.81M | 29.34M |
Financing income | ---- | ---- | ---- | ---- | 1.25%5.85M | 124.84%3.58M | 14.98%5.77M | --1.59M | 13.29%5.02M | --4.43M |
Financing cost | -65.20%4.58M | 63.95%2.09M | 587.14%13.15M | --1.28M | -207.52%-2.7M | ---2.54M | ---878K | ---- | ---- | ---- |
Special items of earning before tax | -284.82%-284.01K | -241.42%-132.3K | --153.67K | --93.55K | ---- | ---- | ---- | ---- | ---- | ---- |
Earning before tax | -49.53%51.06M | -25.11%39.11M | 3.44%101.17M | 52.22M | 66.09%97.81M | 15.42%16.58M | 47.86%58.89M | 14.36M | 17.93%39.83M | 33.77M |
Tax | 52.51%-10.8M | 27.13%-8.31M | -9.35%-22.74M | ---11.41M | -53.71%-20.79M | -20.21%-4.04M | -24.17%-13.53M | ---3.36M | -17.05%-10.89M | ---9.31M |
After-tax profit from continuing operations | -48.67%40.26M | -24.54%30.8M | 1.84%78.43M | 40.81M | 69.78%77.02M | 13.96%12.54M | 56.78%45.36M | 11M | 18.26%28.93M | 24.47M |
Earning after tax | -48.67%40.26M | -24.54%30.8M | 1.84%78.43M | 40.81M | 69.78%77.02M | 13.96%12.54M | 56.78%45.36M | 11M | 18.26%28.93M | 24.47M |
Minority profit | -46.68%828.74K | 14.82%781.19K | 28.78%1.55M | --680.39K | 1,911.67%1.21M | ---226K | --60K | ---- | ---- | ---- |
Profit attributable to shareholders | -48.71%39.43M | -25.21%30.01M | 1.41%76.88M | 40.13M | 67.34%75.81M | 16.02%12.76M | 56.57%45.3M | 11M | 18.26%28.93M | 24.47M |
Basic earnings per share | -54.55%0.3 | -42.50%0.23 | -13.16%0.66 | 0.4 | 0.76 | |||||
Diluted earnings per share | -54.55%0.3 | -42.50%0.23 | -13.16%0.66 | 0.4 | 0.76 | |||||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | Unqualified Opinion |
Auditor | Dahua Certified Public Accountants (Special General Partnership) | -- | KPMG | -- | KPMG | -- | KPMG | -- | KPMG | KPMG |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data
No Data